Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead

Everardo González-González, Mario Moisés Alvarez*, Alan Roberto Márquez-Ipiña, Grissel Trujillo-de Santiago, Luis Mario Rodríguez-Martínez, Nasim Annabi, Ali Khademhosseini

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

17 Citations (Scopus)


The 2014 Ebola outbreak, the largest recorded, took us largely unprepared, with no available vaccine or specific treatment. In this context, the World Health Organization declared that the humanitarian use of experimental therapies against Ebola Virus (EBOV) is ethical. In particular, an experimental treatment consisting of a cocktail of three monoclonal antibodies (mAbs) produced in tobacco plants and specifically directed to the EBOV glycoprotein (GP) was tested in humans, apparently with good results. Several mAbs with high affinity to the GP have been described. This review discusses our current knowledge on this topic. Particular emphasis is devoted to those mAbs that have been assayed in animal models or humans as possible therapies against Ebola. Engineering aspects and challenges for the production of anti-Ebola mAbs are also briefly discussed; current platforms for the design and production of full-length mAbs are cumbersome and costly.

Original languageEnglish
Pages (from-to)53-68
Number of pages16
JournalCritical Reviews in Biotechnology
Issue number1
Publication statusPublished - 2 Jan 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 Taylor & Francis.

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Applied Microbiology and Biotechnology


Dive into the research topics of 'Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead'. Together they form a unique fingerprint.

Cite this